FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV: CYTO), discusses the company’s innovative approach to addressing bacterial infections through bacteriophage technology.
Theriault draws attention to the technology’s relevance in light of recent events, such as the McDonald’s E. coli outbreak, demonstrating the urgent need for alternative solutions to bacterial contamination. This real-world example highlights the potential applications of Cytophage’s technology in food safety.
The CEO discusses two key developments: a new poultry product, addressing immediate needs in the agriculture sector, and upcoming treatments for human health applications, suggesting significant market expansion potential
Dr. Theriault positions Cytophage at the forefront of the growing antibiotics alternative market, particularly important given increasing global concerns about antibiotic resistance. This strategic positioning could offer significant opportunities as the market for alternative treatments expands.
Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
